Trials / Withdrawn
WithdrawnNCT04252612
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pramlintide | SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide. |
Timeline
- Start date
- 2020-01-30
- Primary completion
- 2023-06-26
- Completion
- 2023-06-26
- First posted
- 2020-02-05
- Last updated
- 2023-06-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04252612. Inclusion in this directory is not an endorsement.